ગુજરાત થેમિસ બાયોસિન શેયર પ્રાઇસ

Pharmaceuticals company Gujarat Themis Biosyn announced Q4FY26 & FY26 results Financial Highlights: Income from Operations (Revenue): For Q4FY26, Income from Operations stood at Rs 4,423.30 lakh, registering a growth of 1.99% QoQ compared to Rs 4,336.82 lakh in Q3FY26. On a YoY basis, it increased by 17.22% from Rs 3,773.62 lakh in Q4FY25. Annual Income from Operations: For FY26, Income from Operations was reported at Rs 16,582.28 lakh, showcasing a growth of 9.96% YoY against Rs 15,079.99 lakh in FY25. Total Income: In Q4FY26, Total Income reached Rs 4,515.41 lakh, reflecting an increase of 3.13% QoQ from Rs 4,378.45 lakh in Q3FY26, and an increase of 15.53% YoY from Rs 3,908.38 lakh in Q4FY25. Annual Total Income: For the full year FY26, Total Income stood at Rs 16,825.09 lakh, higher by 9.80% YoY compared to Rs 15,323.23 lakh in FY25. Net Profit After Tax: Net Profit for Q4FY26 was Rs 1,089.12 lakh, marking a decline of 12.62% QoQ compared to Rs 1,246.46 lakh in Q3FY26, and a decrease of 9.22% YoY against Rs 1,199.81 lakh in Q4FY25. Annual Net Profit: For FY26, the Net Profit stood at Rs 4,668.15 lakh, down by 4.29% YoY compared to Rs 4,877.17 lakh in FY25. Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was reported at Rs 1,089.54 lakh, and for the full year FY26, it amounted to Rs 4,668.65 lakh. Earnings Per Share (EPS): Basic and Diluted EPS for Q4FY26 was Rs 1.00, compared to Rs 1.14 in Q3FY26 and Rs 1.10 in Q4FY25. For the full year FY26, the EPS stood at Rs 4.28, compared to Rs 4.48 in FY25. Business & Segment Highlights: Dividend: The Board of Directors recommended a final dividend of Re 0.67 (67%) per equity share having a face value of Re 1 each, aggregating to Rs 7,30,06,728 for FY26, subject to the approval of shareholders at the ensuing Annual General Meeting. Segment Performance: The company operates only in one Business Segment, i.e., manufacturing of fermentation-based pharmaceutical intermediates and APIs. Hence, there are no reportable segments as per Ind AS-108, and the financial results fully reflect the performance of this single segment. Preferential Issue: The Board considered and approved a proposal for the preferential issue of equity shares to Non-Promoters. A Preferential Issue Committee has been constituted to decide and finalize the terms and conditions of the proposed issue. Statutory Updates: The company recognized an incremental impact of Rs 14.49 lakh in the financial results due to the assessment of financial impacts arising from the new Labour Codes notified by the Government of India. Key Appointments: The Board approved the appointment of M/s. Raja Dutta & Co., Cost Accountants as the Cost Auditor of the company for FY27. Result PDF

• ટ્રેન્ડલાઇન
• 2 અઠવાડિયા 3 દિવસ પહેલાં

ફાર્માસ્યુટિકલ્સ કંપની ગુજરાત થેમિસ બાયોસિનએ Q3FY26 પરિણામોની આવકની જાહેરાત કરી: Q3FY25 દરમિયાન ₹ 3,951.98 લાખ સામે ₹ 4,336.82 લાખ, ફેરફાર 10%. પીબીટી: Q3FY25 દરમિયાન રૂ. 1,740.04 લાખ સામે રૂ. 1,687.34 લાખ, -3% બદલો. પીએટી: Q3FY25 દરમિયાન રૂ. 1,297.23 લાખ સામે રૂ. 1,246.46 લાખ, -4% બદલો. ઇપીએસ: Q3FY26 માટે ₹ 1.14. પરિણામની PDF

• ટ્રેન્ડલાઇન
• 4 મહિના પહેલાં

Pharmaceuticals company Gujarat Themis Biosyn announced Q4FY23 & FY23 results: Q4FY23: Revenue from Operations stood at Rs 28.17 crore in Q4FY23, as against Rs 28.76 crore in Q4FY22 EBITDA for the quarter was Rs 14.93 crore as against Rs 13.08 crore in Q4FY22, increase of 14.12%. EBITDA Margin stood at 52.98%, up by 751 bps Q4FY23 PAT stood at Rs 11.69 crore as against profit of Rs 9.79 crore in Q4FY22 EPS for the quarter stood at Rs 8.05 FY23: Revenue from Operations stood at Rs 148.97 crore in FY23, vs Rs 114.85 crore in FY22, up 29.71% EBITDA for FY23 was Rs 74.22 crore as against Rs 58.05 crore in FY22, increase of 27.86% EBITDA Margin stood at 49.82% FY23 PAT stood at Rs 57.97 crore as against PAT of Rs 43.62 crore in FY22 EPS for the year stood at Rs 39.90 Result PDF

• ટ્રેન્ડલાઇન
• 3 વર્ષો પહેલા